Navigation Links
Omeros to Host Conference Call Monday, October 25 at 4:00 p.m. ET To Provide Corporate Update
Date:10/22/2010

SEATTLE, Oct. 22 /PRNewswire-FirstCall/ -- Omeros Corporation (Nasdaq: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system, today announced that the Company will host a webcast conference call Monday afternoon, October 25, 2010 at 4:00 p.m. Eastern time to provide a corporate update. Gregory A. Demopulos, M.D., chairman and chief executive officer, will provide remarks which will be followed by a question and answer session.

To access the live call by telephone, please dial 800-901-5217 (United States and Canada) or 617-786-2964 (International). The passcode is 26273994.  In addition, the live conference call will be webcast and can be accessed on the "Events" page of the Company's website at http://www.omeros.com.

A replay of the webcast will be available on the Company's website for one week.  A telephone replay will also be available for one week starting at 7:00 p.m. Eastern time on October 25, which can be accessed by dialing 888-286-8010 (United States and Canada) or 617-801-6888 (International) and entering passcode 82437761.

About Omeros Corporation

Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. The Company's most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing a wide range of surgical and medical procedures. Omeros has five ongoing clinical development programs, including four from its PharmacoSurgery(TM) platform, the most advanced of which is in a Phase 3 clinical program, and one from its Addiction program. Omeros may also have the near-term capability, through its GPCR program, to add wholly new drug targets to the market. Behind its clinical candidates and GPCR platform, Omeros is building a diverse pipeline of antibody and small-molecule preclinical programs targeting inflammation and central nervous system disorders.


'/>"/>
SOURCE Omeros Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Omeros to Present at the BioCentury NewsMakers Conference
2. Omeros Enrolls First Patient in Phase 2b Clinical Trial Evaluating OMS302 in Patients Undergoing Cataract Surgery
3. Omeros Successfully Unlocks Orphan GPCRs
4. Omeros Selects Clinical Candidate for MASP-2 Program With Potential Applicability to Multiple Inflammatory Disorders
5. Omeros Reports Additional Phase 2 Data Showing Multiple Clinical Benefits In Patients Undergoing Meniscectomy Surgery
6. Omeros Announces National Institute on Drug Abuses Support for Phase 2 Clinical Study in Addiction Program
7. Daniel K. Spiegelman Elected to Board of Directors of Omeros
8. Omeros Corporation to Host Third Quarter 2009 Financial Results Conference Call on November 19
9. Omeros Prices Initial Public Offering of Common Stock at $10.00 Per Share
10. Omeros Receives $3.1 Million Milestone Payment from The Stanley Medical Research Institute for Schizophrenia Program
11. Omeros and The Parkinsons Institute and Clinical Center Enter into a Collaboration Agreement to Evaluate Novel Target for the Treatment of Movement Disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)...  Mirabilis Medical, a Seattle ... surgery, announced today CE Mark authorization for marketing ... fibroids throughout the European Union.  The company simultaneously ... US Food and Drug Administration to begin a ... United States.  The Mirabilis System combines high-speed therapeutic ...
(Date:3/23/2017)... Mar 23, 2017 Research and Markets has ... Trends - Industry Forecast to 2025" report to their offering. ... The Global ... 6.9% over the next decade to reach approximately $3.5 billion by ... forecasts for all the given segments on global as well as ...
(Date:3/23/2017)... , March 23, 2017  Transportation Insight, a ... an end-to-end supply chain management firm with expertise serving ... Product Solutions Rick Zaffarano was named a ... the Supply Chain by the only publication exclusively dedicated ... food supply chain. "Rick has brought to ...
Breaking Medicine Technology:
(Date:3/23/2017)... ... March 23, 2017 , ... A recent report from the National ... preparation programs. The NCTQ report suggests, based on a review of GPA and SAT/ACT ... teacher quality in the U.S. It argues that this higher bar should be set ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... Texas ... located at 960 Gruene Road in Building 2. The clinic is the group’s second ... Bennett, PT, says opening the company’s second New Braunfels location brings things full circle ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... The MBI “Hall of Fame” recognizes the ... acts have had a significant impact on the careers of all others involved. ... Inc. was inducted into the MBI’s Hall of Fame. The induction took place during ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... March is ... that pack a punch when it comes to maintaining good health. Every day, two ... minutes, your kidneys filter every drop of your blood, eliminating waste, regulating fluid levels ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... ... investment in Los Angeles based healthcare technology company California Healthcom Group (CHG). ... the US, and healthcare arena. With headquarters in California, CHG is a growing, ...
Breaking Medicine News(10 mins):